1		
2		
3		
4		
5		
6		Using genome-wide association results to identify drug
7		repurposing candidates
8		
9		Nathaniel Bell ¹ , Emil Uffelmann ¹ , Eva van Walree ^{1,3} , Christiaan de Leeuw ¹ , & Danielle
10		Posthuma ^{1,2}
11		
12	1	Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive
13		Research, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam, The
14		Netherlands
15		
16	2	Department of Child and Adolescent Psychiatry and Pediatric Psychology, Section
17		Complex Trait Genetics, Amsterdam Neuroscience, Vrije Universiteit Medical Center,
18		Amsterdam, The Netherlands.
19		
20	3	Department of Clinical Genetics, Amsterdam UMC, University of Amsterdam,
21		Amsterdam, The Netherlands
22		

23 Abstract

24 Drug repurposing may provide a solution to the substantial challenges facing de novo drug 25 development. Given that 66% of FDA-approved drugs in 2021 were supported by human genetic 26 evidence, drug repurposing methods based on genome wide association studies (GWAS), such as 27 drug gene-set analysis, may prove an efficient way to identify new treatments. However, to our 28 knowledge, drug gene-set analysis has not been tested in non-psychiatric phenotypes, and 29 previous implementations may have contained statistical biases when testing groups of drugs. 30 Here, 1201 drugs were tested for association with hypercholesterolemia, type 2 diabetes, 31 coronary artery disease, asthma, schizophrenia, bipolar disorder, Alzheimer's disease, and 32 Parkinson's disease. We show that drug gene-set analysis can identify clinically relevant drugs 33 (e.g., simulating for hypercholesterolemia [p = 2.82E-06]; mitiglinide for type 2 diabetes [p = 2.82E-06]; mitiglinide for type 34 2.66E-07]) and drug groups (e.g., C10A for coronary artery disease [p = 2.31E-05]; insulin 35 secretagogues for type 2 diabetes [p = 1.09E-11]) for non-psychiatric phenotypes. Additionally, 36 we demonstrate that when the overlap of genes between drug-gene sets is considered we find no 37 groups containing approved drugs for the psychiatric phenotypes tested. However, several drug 38 groups were identified for psychiatric phenotypes that may contain possible repurposing 39 candidates, such as ATC codes J02A (p = 2.99E-09) and N07B (p = 0.0001) for schizophrenia. 40 Our results demonstrate that clinically relevant drugs and groups of drugs can be identified using 41 drug gene-set analysis for a number of phenotypes. These findings have implications for quickly 42 identifying novel treatments based on the genetic mechanisms underlying diseases. 43

44 Keywords: genome-wide association study, drug repurposing, gene-set analysis.

46 Over the last 15 years, the use and effectiveness of genome-wide association studies (GWAS) have 47 developed rapidly, resulting in the discovery of over 270,000 phenotypically associated genetic 48 variants^{1,2}. While translating GWAS findings into use for pharmacological and clinical purposes has 49 been challenging, seminal work by Nelson et al. and King et al. demonstrated that drugs with 50 genetic support for efficacy were 2-5 times more likely to gain approval status compared to compounds with no such evidence^{3,4}. In fact, 66% of FDA-approved drugs in 2021 are supported 51 52 by human genetic evidence that link the compounds to their gene product targets⁵. GWAS results 53 have been used as early as 2009 to prioritize novel targets for pharmaceuticals⁶. For example, 54 Wang et al identified the IL12/IL23 pathway as a novel target for Crohn's disease, which supported 55 the subsequent development of Ustekinumab, an antibody that binds with IL12 and IL23^{6,7}.

56 However, the development of novel pharmaceuticals is a time and financially intensive 57 process, averaging 12.8 years and \$2.6 billion dollars for a single new medication^{8,9}. Despite wide advances across science and technology in the past 60 years, the cost for approved drugs per billion 58 59 spent has seen an 80-fold increase after adjusting for inflation¹⁰. Additionally, the development of 60 novel drugs for psychiatric and neurological conditions has been particularly affected, with several 61 large pharmaceutical companies shutting down research and development for psychiatric disorders 62 entirely¹¹. Given the size of the challenges facing *de novo* drug development, interest has turned 63 towards drug repurposing, the process of identifying new clinical indications (the phenotype a 64 drug is approved to treat) for currently approved medications¹². Moreover, the vast quantities of 65 GWAS results provide excellent data regarding possible gene targets to be leveraged for drug 66 repurposing. To date, many methods have been created to repurpose drugs using GWAS summary 67 statistics, including candidate gene approaches, Mendelian randomization, pharmagenic enrichment scores, transcriptomic signature matching, and drug gene-set analysis^{13–17}. 68

69 Drug gene-set analysis, an approach first published by De Jong and Breen¹⁸, can be used to 70 identify candidate drugs based on GWAS results. Gene-set, or pathway, analysis involves mapping 71 genetic variants (e.g., single nucleotide polymorphisms [SNPs], copy number variants [CNVs]) to 72 genes, and grouping genes into sets based on, for example, a priori biological functions or co-73 expression networks, and testing each gene set for association with the phenotype^{19,20}. For drug 74 gene-set analysis, gene sets are created for drugs based on known biological and/or chemical 75 properties. For example, a drug-gene set can be made of the genes that code the proteins targeted 76 by a specific drug, and this gene set can be tested for association with a phenotype. While De Jong 77 & Breen found no gene-sets to be significantly associated with schizophrenia, their nominally 78 significant results included the known schizophrenia drug trifluoperazine, and metoclopramide 79 and neratinib, which target dopamine receptors and tyrosine kinases (both implicated in 80 schizophrenia)¹⁸. This method has been continued by Gaspar and colleagues, who developed the drug repurposing tool Drug Targetor, which is largely based on drug gene-set analysis^{17,21}. 81

82 However, while drug gene-set analysis has been tested in schizophrenia and bipolar 83 disorder, it has never been verified in non-psychiatric phenotypes and, to our knowledge, no drugs 84 have ever been found to be significantly associated with schizophrenia. Additionally, previous 85 research testing groups of drugs for associations have used methods that violated statistical 86 assumptions of independence¹⁷. Here, we apply drug gene-set analysis to eight phenotypes -87 hypercholesterolemia (i.e., high cholesterol), type 2 diabetes, coronary artery disease, asthma, 88 schizophrenia, bipolar disorder, Alzheimer's disease, and Parkinson's disease - and use a novel 89 statistical approach to test if groups of drugs are enriched for genetic signal associated with a 90 phenotype while accounting for the covariance between drugs. Our objectives were first, to assess 91 the ability of drug gene-set analysis at prioritizing clinically relevant drugs for each phenotype, 92 and second, to identify candidate drugs for repurposing for the phenotypes investigated.

93 Results

94 We extracted data for drug-gene targets and interactions from the Clue Repurposing Hub and the 95 Drug Gene Interaction Database and created a gene set for each drug (n = 1201) composed of the 96 genes whose protein products are known to be targeted by or interact with the drug in question 97 (Figure 1A)^{22,23}. To test drug-gene set associations, competitive gene-set analysis was performed using the MAGMA software tool for each of the eight phenotypes¹⁹ while conditioning on a gene 98 99 set of all drug target genes in our data (n = 2281; Methods). This was done to ensure that 100 significant drug-gene set associations were due to effects unique to drug pathways, and not due to 101 common properties shared by all drug target genes (e.g., many gene products targeted by drugs 102 are receptors). For the individual drug-gene sets see Supplementary Table S1.

103

104 Individual drug-gene set results

105 We identified 22 significant drug-trait associations across the eight phenotypes we investigated 106 using drug gene-set analysis (Table 1 & 2; Fig 1A). Drugs were significantly associated with each 107 of the phenotypes except for asthma and Parkinson's disease. For the non-psychiatric/neurological 108 phenotypes, many of our results included drugs approved to treat the diseases in question. For 109 instance, all 4 of the drugs associated with type 2 diabetes – glipizide, glyburide, mitiglinide, and 110 repaglinide – are approved for type 2 diabetes²⁴⁻²⁶ (Tables 1 & 2). Similarly, statin drugs (e.g., 111 pravastatin and atorvastatin) were associated with both coronary artery disease and 112 hypercholesterolemia, which are used to lower LDL cholesterol and prevent myocardial 113 infarctions²⁷. Likewise, lomitapide and fenofibrate, which were also associated with coronary 114 artery disease, are drugs used to treat hypercholesterolemia, a known risk factor for coronary 115 artery disease^{28–30}. We found no significant associations between approved psychiatric drugs and 116 the psychiatric phenotypes that were tested. However, the antiepileptic drug gabapentin was

- 117 significantly associated with schizophrenia, which is known to have some efficacy in treating
- 118 psychiatric disorders³¹. For all individual drug gene-set analysis results see Supplementary Tables
- 119 S2 S9.
- 120

121 Table 1. Summary of results

Phenotype	Total	Total	% Approved	Ν	N Signif.	% Signif.
	tested	Approved		Signif.	and	of
				drugs	approved	approved
						drugs
Hypercholesterolemia	1162	8	0.68%	5	3	37.5%
Type 2 diabetes	1056	30	2.84%	4	4	13.33%
Coronary artery	1172	14	1.19%	6	1	7.14%
disease						
Asthma	1172	29	2.47%	0	0	0%
Schizophrenia	1172	45	3.84%	4	0	0%
Bipolar disorder	1172	13	1.11%	2	0	0%
Alzheimer's disease	1172	5	0.42%	1	0	0%
Parkinson's disease	1172	29	2.47%	0	0	0%

Total tested = total number of drug-gene sets tested for each phenotype; Total approved = number of approved drug-gene sets tested for each phenotype; % approved = % of total drugs tested that are approved for each phenotype; N signif. drugs = total number of significant drugs for each phenotype (see Table 2 for all significant drugs). Bonferroni-corrected p-value thresholds for hypercholesterolemia = 0.05 / 1162 = 4.3E-05, for type 2 diabetes = 0.05 / 1056 = 4.73E-05, and for coronary artery disease, asthma, schizophrenia, bipolar disorder, Alzheimer's disease, and Parkinson's disease = 0.05 / 1172 = 4.27E-05; N signif. and approved = number of significant drugs that are approved for the given phenotype; % signif. of

approved drugs = % of the total number of approved drugs for a tested phenotype that were significant.



13

Figure 1 Overview of drug gene-set analysis. (A) Gene sets were created for every drug (n = 1201) consisting of 133 the genes whose protein products are targeted by or interact with that drug. Since similar drugs share gene targets it 134 is possible for overlap of genes to occur between drugs. MAGMA was used for gene-set analysis to test for significant 135 relationships between drug-gene sets and each phenotype. Drug-gene sets were tested using a conditional competitive 136 gene-set analysis (Methods). (B) Drug groups were tested for enrichment of genetic signal using a modified multiple 137 linear regression model. This was done for ATC III groups (n = 85), mechanism of action drug groups (n = 79), and 138 clinical indication drug groups (n = 118) with n > 5 (Methods). (C) Lastly, gene sets were created for each subcategory 139 of each grouping method (i.e., ATC III codes, clinical indications, and mechanisms of action) and tested for association 140 using the same MAGMA protocol as drugs in panel A (Methods). 141

Drug gene set	Phenotype	Approved	N genes	MAGMA p
atorvastatin	TCL	No	60	1.77E-11
lomitapide	TCL	Yes	4	7.33E-08
pravastatin	TCL	Yes	34	6.15E-11
saroglitazar	TCL	No	2	3.22E-05
simvastatin	TCL	Yes	52	2.82E-06
mitiglinide	T2D	Yes	4	2.66E-07
glyburide	T2D	Yes	19	2.29E-05
repaglinide	T2D	Yes	15	9.01E-16
glipizide	T2D	Yes	6	1.08E-05
aminocaproic acid	CAD	No	3	1.59E-11
atorvastatin	CAD	No	61	8.40E-08
fenofibrate	CAD	No	28	7.63E-06
lomitapide	CAD	No	4	3.96E-11
lovastatin	CAD	Yes	43	3.38E-06
pravastatin	CAD	No	35	1.59E-07
amlodipine	SCZ	No	12	1.51E-05
benidipine	SCZ	No	2	1.32E-05
felodipine	SCZ	No	13	1.53E-05
gabapentin	SCZ	No	38	3.80E-08
manidipine	BIP	No	2	2.64E-06
nilvadipine	BIP	No	2	2.64E-06
lubiprostone	ALZ	No	2	3.76E-06

142 **Table 2. Individual drug-gene set results for all phenotypes**

143 Drug-gene set = drugs whose gene set was significant after Bonferroni correction for the number of drug 144 gene sets tested (see Table 1 for number of drugs tested for each phenotype); Phenotype = the phenotype 145 the drug was associated with. TCL = hypercholesterolemia, T2D = type 2 diabetes, CAD = coronary artery 146 disease, BIP = bipolar disorder, SCZ = schizophrenia, ALZ = Alzheimer's disease; Approved = whether the 147 drug is approved to be used for the phenotype it was associated with; N genes = number of genes in the 148 drug gene set; MAGMA p = p-value for individual drug gene-sets from a competitive gene-set analysis while 149 conditioning on a gene set of all drug target genes in the data; No drugs were significantly associated with 150 Asthma or Parkinson's disease.

152 Drug group enrichment

153 Drug gene sets were grouped in three ways: by Anatomical Therapeutic Classification (ATC) III 154 code, by clinical indication, and by the mechanism of action. Previous research that tested for 155 enrichment of genetic signal within groups of drug gene sets used drug enrichment curves derived 156 from a Wilcoxon Mann Whitney U test¹⁷. However, due to the overlap of genes between drug gene 157 sets, the assumption of data independence needed for a Wilcoxon Mann Whitney U test is not 158 valid. Thus, here we instead employed a multiple linear regression approach, modeling the drug 159 group membership as a predictor of the MAGMA drug gene-set t-statistic, to test whether drugs in 160 that drug group exhibited (on average) more strongly associated drug gene sets than other drugs. 161 Overlap between gene sets is accounted for through the residual covariance matrix of the 162 regression model.

163 Each drug group with 5 or more drugs within the ATC (n = 85), mechanism of action (n =164 79), and clinical indication (n = 118) categories was tested for enrichment of genetic signal using 165 the method above. Bonferroni correction was applied by correcting for the number of drug groups 166 tested within each of the three grouping methods, and then using a family-wise correction for the 167 number of grouping methods used. Therefore, the Bonferroni-corrected p-value threshold was 168 (0.05/85) / 3 = 0.00019 for ATC drug groups, (0.05/79) / 3 = 0.00021 for mechanism of action 169 drug groups, and (0.05/118)/3 = 0.00014 for clinical indication drug groups. For all drug groups 170 see Supplementary Tables S10 – S12, and for the drug group enrichment results see Supplemental 171 Table S13 – S22.

As seen in Figure 2 (top), we identified 14 drug groups that were significantly enriched for genetic signal across the 8 phenotypes we examined. For the non-psychiatric/neurological phenotypes, we found at least one drug group containing one or more drugs approved for the phenotype tested. For hypercholesterolemia, we identified two drug groups where more than 50%

176 of the drugs were approved for hypercholesterolemia (C10A and HMGCR inhibitors), and we 177 identified the mechanism of action group insulin secretagogues for type 2 diabetes, which contains 178 only drugs approved for type 2 diabetes. None of the drug groups that were associated with our 179 psychiatric and neurological phenotypes contained approved drugs. However, the ATC code N07B 180 - drugs used for addictive disorders - that is associated with schizophrenia contains several drugs 181 (e.g., naltrexone, buprenorphine) that have shown significant improvements in treating both 182 positive and negative symptoms in the disorder³². As seen in the bottom panels of Figure 2, none 183 of the clinical indication drug groups for the phenotypes we examined were significantly associated 184 with our phenotype after correction for multiple tests. The clinical indication groups for Parkinson's 185 disease, type 2 diabetes, and hypercholesterolemia were nominally enriched for genetic signal for 186 each of their respective phenotypes.



Figure 2 Drug group enrichment. Drug groups were tested for enrichment of genetic signal with each phenotype. The left panels show the -log₁₀ p-values for each drug group, and the right panels show the percentage of approved drugs in the group. The top panels show all drug groups that are significant after multiple testing correction. The bottom panels portray the drug groups containing all approved drugs for each of the 8 phenotypes that were tested. TCL = hypercholesterolemia; T2D = type 2 diabetes; CAD = coronary artery disease; AST = asthma, SCZ = schizophrenia; BIP = bipolar disorder; PKD = Parkinson's

To examine the genes driving the significant results seen in the top panel of Figure 2, we generated heatmaps of the drug-gene sets for the most significant drug groups for each phenotype; insulin secretagogues for type 2 diabetes (Fig 3A), the clinical indication drug group of urticaria for asthma (Fig 3B), ATC code J02A for schizophrenia (Fig 3C), and ATC code A04A for Alzheimer's disease (Fig 3D). For the C10A heatmaps associated with hypercholesterolemia and coronary artery disease see Supplemental Figures S1 and S2.

202 As seen in Figure 3A, the genes with the highest MAGMA $-\log_{10}$ p-values targeted by insulin 203 secretagogues are KCNQ1, TCF7L2, PPARy, IGF2BP2, and KCNJ11. All these genes are known to be 204 associated with type 2 diabetes and affect biological processes like insulin secretion and fat storage 205 in adipose tissue^{33,34}. For the clinical indication drug group urticaria (Fig 3B), there are several 206 genes with evidence linking them to asthma. Namely, research has indicated that the *PPAR* δ gene 207 targeted by desloratadine may be a promising therapeutic target for asthma, with desloratadine 208 itself – an allergy medication – having shown efficacy in treating seasonal allergic asthma 35,36 . 209 Moreover, another study found that *EHMT2* was differentially expressed in patients with asthma 210 compared to healthy controls³⁷. The targets of drugs in the ATC J02A group also contain genes 211 related to schizophrenia. Antigen levels for DPYD were found to be elevated in individuals with 212 schizophrenia compared with healthy controls, and it is known to be associated with schizophrenia 213 via previous genome-wide association studies^{38,39}. Moreover, there is evidence indicating that 214 splicing variation of CYP2D6 may play a role in schizophrenia as well⁴⁰. Lastly, the ATC group 215 A04A associated with Alzheimer's disease targets a number of serotonergic receptors, which have 216 shown promise as therapeutic targets in animal models by reducing levels of amyloid-beta⁴¹. 217 Interestingly, all of the drug groups depicted appear to be driven by a variety of genes, as opposed 218 to a small number of genes targeted by all drugs in a group (with the exceptions of PPARy, KCNJ11, 219 and ABCC8 for the insulin secretagogues).



220

221 222

223 Figure 3 Heatmaps of drug group enrichment results. The heatmaps depict the drug-gene sets from 224 drug groups that were significantly associated with a phenotype, with color signifying the gene's -log₁₀ p-225 value from MAGMA. Panel (A) depicts drug-gene sets from the insulin secretagogues group associated 226 with type 2 diabetes, panel (B) illustrates the drug-gene sets from the clinical indication group urticaria 227 associated with asthma, panel (C) shows the drug-gene sets from ATC code J02A associated with 228 schizophrenia, and panel (D) portrays the drug-gene sets from ATC code A04A associated with Alzheimer's 229 disease. Drug gene set names are listed on the y-axis, and gene names are listed on the x-axis. Color = -230 log₁₀ p-value from gene association tests in MAGMA.

231 Next, we compared the gene targets of approved drugs for each phenotype to further investigate 232 why drug-gene set analysis was better at identifying approved drugs for the non-233 psychiatric/neurological phenotypes that were tested. As seen in Figure 4, there are 38 gene targets 234 of approved drugs (8.44% of drug target genes) that are significant after Bonferroni correction for 235 the non-psychiatric/neurological phenotypes investigated, compared to 17 significant gene targets 236 (3.21% of drug target genes) for drugs approved for the psychiatric and neurological phenotypes. 237 Moreover, each of the four non-psychiatric/neurological phenotypes has at least 4 significant genes 238 targeted by approved drugs, while bipolar disorder and Parkinson's disease have only 1 significant 239 gene targeted by an approved drug, and Alzheimer's disease has none. This may explain why none 240 of the significant drug groups associated with the psychiatric and neurological phenotypes 241 contained any drugs approved specifically for those disease and disorders.

242

243



245 Figure 4 Manhattan plots of gene targets for approved drugs. The top panel depicts the gene-level 246 Manhattan plot for the targets of approved drugs for the four non-psychiatric/neurological phenotypes (n =247 450), and the bottom panel depicts the same for the psychiatric/neurological phenotypes (n = 530). Genes 248 that are labeled are significant after Bonferroni correction for their respective phenotype (since the number 249 of genes tested varied per phenotype, different Bonferroni thresholds were applied to each phenotype; see 250 Methods). Color = phenotype; shape = even and odd chromosomes; TCL = hypercholesterolemia; T2D = 251 type 2 diabetes; CAD = coronary artery disease; AST = asthma, SCZ = schizophrenia; BIP = bipolar 252 disorder; PKD = Parkinson's disease; ALZ = Alzheimer's disease.

- 253
- 254

256 Merged drug gene-set analysis

257 Some drug-gene sets have a very small number of gene targets, resulting in lower power to detect associations with phenotypes²⁰. Additionally, many drug categories in our data do not 258 259 contain enough drugs to test for enrichment. Therefore, to be able to include drug targets with 260 small gene set sizes and to test association for drug categories with low numbers of drugs, we also 261 created gene sets by grouping drugs again by ATC III code, clinical indication, and mechanism of 262 action. For each category within the grouping methods, a single gene set was created made up of 263 all the gene targets for drugs in the group (Figure 1C), resulting in 164 ATC III code gene sets, 515 264 clinical indication gene sets, and 354 mechanism of action gene sets (Tables S23 - S25). 265 Competitive gene-set analysis was performed with the same protocol used when testing individual 266 drug-gene sets for each of the three types of grouped drug-gene sets (Methods). We identified 32 267 significant categorical gene set-trait relationships, with every phenotype but asthma and 268 Parkinson's disease having at least one associated gene set. For all significant categorical drug gene 269 sets see Supplementary Table S26, and for all categorical drug-gene set results see Supplementary 270 Tables S27 – S50.

271

272 Drug similarity networks

For each phenotype, we created network graphs to investigate how the top drugs per phenotype cluster based on their Jaccard similarity coefficient⁴² (Figure 5), which is calculated using the proportion of gene targets shared by both drugs (see Methods). Central nodes in each network graph were defined using all drugs with a MAGMA competitive gene-set analysis p-value < 0.01 per phenotype. All drugs with a Jaccard similarity of 0.25 or greater with a central node were included as peripheral nodes. Figure 5A displays the similarity network graph for drugs

associated with hypercholesterolemia and Figure 5B illustrates the similarity of drugs associatedwith schizophrenia.

281 As may be expected, statin drugs approved for hypercholesterolemia tend to cluster 282 together, while the other two significant drugs, lomitapride and probucol, have no similar 283 compounds (Figure 5A). There is also a cluster of PPAR agonists around the significant drug 284 saroglitazar and nominally significant drug bezafibrate, which both target the PPAR α/γ subunits. 285 Figure 5B demonstrates that almost none of the Bonferroni-significant drugs identified using drug 286 gene-set analysis for schizophrenia cluster with approved schizophrenia drugs, with the exception 287 being one approved drug sharing an edge with benidipine. Most nominally significant drugs for 288 schizophrenia (Figure 5B) appear in the same large cluster, which ranges from antiepileptics in 289 one subcluster (e.g., ethosuximide), calcium channel blockers in the middle (e.g., felodipine), and 290 ACE inhibitors on the other side (e.g., quinapril). The exception is gabapentin, which appears by 291 itself connected to only one other drug, spironolactone. Interestingly, spironolactone has been 292 found to improve schizophrenia symptoms in mice by acting as an antagonist to the NRG1-ERBB4 293 signaling pathway, and is currently being tested in humans as an add-on treatment for SCZ^{43} . The 294 rest of the approved schizophrenia drugs (triangles) appear in the cluster centered around 295 amisulpride, azaperone, domperidone, and perospirone. For network graphs of all phenotypes see 296 the Supplemental materials (Figures S3 – S7).



298

Figure 5 Drug similarity networks. Drug similarity was calculated using the Jaccard index to measure the proportion of shared gene targets between every pair of drugs. Drugs nominally associated with our phenotypes (p < 0.01) were used as central nodes, with peripheral nodes being any drug with a Jaccard similarity > 0.25 with any central node. Panel (A) displays the results for hypercholesterolemia, and (B) shows the network for drugs associated with schizophrenia. Triangle = approved drug for the phenotype, square = Bonferroni-significant drug that is not approved for the phenotype, edge width = Jaccard similarity coefficient.

306 Discussion

307 In the current study, we applied drug gene-set analysis to four non-psychiatric/neurological 308 phenotypes and four psychiatric/neurological phenotypes, to investigate the performance of drug 309 gene-set analysis at identifying clinically relevant drugs (i.e., drugs approved to treat the 310 phenotypes we examined), and to identify potential repurposing candidates. We found the first 311 drugs whose targets were significantly enriched for genes associated with hypercholesterolemia, 312 type 2 diabetes, coronary artery disease, schizophrenia, and Alzheimer's disease using this method, 313 and identified drugs with the same mechanism of action (calcium channel blockers) as those 314 published in the latest genome-wide association study of bipolar disorder⁴⁴. In all, 22 drug-trait 315 associations were identified across the eight phenotypes we examined. Notably, 4 of the 4 drugs 316 identified for type 2 diabetes are approved to treat type 2 diabetes, and 3 statin drugs were 317 significantly associated with both coronary artery disease and hypercholesterolemia, respectively²⁴⁻ 318 ^{26,45,46}. We also demonstrated that drug gene-set analysis does not have to be used to isolate single 319 drugs for repurposing and can also pinpoint categories of drugs by using two different methods: 320 by testing for the enrichment of individual drugs in a category and by combining gene targets of 321 all drugs in a category into a single gene set, thereby also pointing into the direction of putative 322 novel drug development that fall within an identified category. Specifically, we identified drug 323 groups enriched for genetic signal for hypercholesterolemia, type 2 diabetes, coronary artery 324 disease, and asthma that contained approved drugs for those diseases. Additionally, we found that 325 the clinical indication drug groups for hypercholesterolemia, type 2 diabetes, and Parkinson's disease were nominally enriched. 326

327 Phenotypes that were not enriched for drugs that are already approved for treatment may 328 not reflect a shortcoming of drug gene-set analysis, but more so the gap between the gene products 329 targeted by current treatments and the genes that are most associated with it as measured by

330 genome-wide association studies. Thus, while no approved drugs for the psychiatric/neurological 331 phenotypes examined here were identified, this may be because current treatments for these 332 diseases only target disease symptoms and not the underlying disease mechanisms^{47–50}. The results 333 presented here establish that drug gene-set analysis can identify clinically relevant drugs – with 334 accuracy varying across the phenotypes we examined – and is able to offer new drug candidates 335 for repurposing.

336 Across our drug gene-set analysis results there is evidence for repurposable drugs for 337 several phenotypes. For instance, we find repeated evidence for the potential treatment of 338 schizophrenia with calcium channel blockers. The calcium channel blockers felodipine, 339 amlodipine, and benidipine were significantly associated with schizophrenia after Bonferroni 340 correction. The use of calcium channel blockers in psychiatry has shown mixed efficacy in the 341 literature. Previous research has tested the use of calcium channel blockers for psychiatric disorders and found them ineffective, although many of these studies used first-generation drugs (e.g., 342 verapamil)⁵¹. Recent research has found that calcium channel blocker use is associated with 343 344 reduced illness severity for schizophrenia and lower rates of psychiatric admission and self-harm 345 during psychosis^{52,53}. Additionally, Lintunen et al. found that calcium channel blocker use was 346 associated with lower risk for psychiatric hospitalization in individuals with schizophrenia, an 347 effect which was specific to the calcium channel blocker subclass of dihydropyridines⁵⁴. This is a 348 significant distinction, as drugs in this subclass are also known to have higher selectivity and 349 permeability across the blood brain barrier, perhaps making them better candidates for psychiatric 350 use than first generation calcium channel blockers⁵¹. Notably, all calcium channel blockers that 351 were identified for both schizophrenia and bipolar disorder, felodipine, amlodipine, benidipine, manidipine, and nilvadipine, are all dihydropyridines⁵⁵. Likewise, one of the two drugs identified 352 353 using drug gene-set analysis in the 2021 genome-wide association study on bipolar disorder was

nisoldipine, which is also a dihydropyridine calcium channel blocker⁴⁴. Thus, further research into
 the use of dihydropyridines in psychiatry may be warranted.

356 Despite the promising results found here, drug gene-set analysis still leaves several 357 questions unanswered regarding repurposable drugs prioritized with this method. First, drug gene-358 set analysis does not specifically test for direct associations between a drug and a phenotype. 359 Rather, it tests whether the gene targets of drugs are enriched for genetic signal that is associated 360 with a phenotype. Second, and perhaps most importantly, is that drug gene-set analysis does not 361 indicate the direction of effect, meaning that drugs identified could either alleviate or exacerbate 362 disease progression and symptoms. Additionally, drug gene-set analysis provides no information 363 on the way a drug interacts with its targets (e.g., agonism versus antagonism). These two 364 limitations mean that drug gene-set analysis may best be used in the first steps of a drug 365 repurposing pipeline, or as one of several methods used to triangulate novel drugs for a 366 phenotype⁵⁶. Drugs prioritized with drug gene-set analysis could be followed up using genomics 367 approaches that consider gene expression (e.g., transcriptomic signature matching) or more 368 statistical approaches like Mendelian randomization¹⁵ or local genetic correlation analysis⁵⁷, using 369 protein levels of the drug-gene targets for each gene in a drug gene set. This may prove tedious 370 for drugs with large gene sets and may fail to capture interaction effects between different proteins. 371 However, transcriptomic signature matching (e.g., correlating gene expression induced by a drug 372 with the gene expression associated with a phenotype) could be an efficient follow-up for large 373 drug-gene sets. Whilst the limitations above are important to note, they do not outweigh the 374 benefits. Given the excessive financial and time challenges facing psychiatric drug development, a 375 cheap in-silico, and quick method for genetically informed drug repurposing, such as drug gene-376 set analysis, may prove invaluable. The drug gene-set analysis pipeline used here is publicly 377 available (Methods) and can be used with any user provided GWAS summary statistics.

378 Materials & Methods

379

Data. *Clue Repurposing Hub.* The Clue Repurposing Hub is a publicly accessible, annotated data set of FDA-approved, clinical trial, and pre-clinical drugs. We extracted gene targets for every FDAapproved drug from the Clue Repurposing Hub that had a known clinical indication, disease category, and mechanism of action (n = 1201).

384

385 *Drug Gene Interaction Database.* To augment the sets of gene targets downloaded from the Clue 386 Repurposing Hub, we queried the Drug Gene Interaction Database API for additional genes 387 targeted by or interacting with each compound in our data set. This database is publicly accessible.

388

389 GWAS. Summary statistics for hypercholesterolemia, coronary artery disease, and Parkinson's disease were downloaded from GWAS Atlas^{58–60} (<u>https://atlas.ctglab.nl/</u>). Summary statistics for 390 391 type 2 diabetes were downloaded from the DIAGRAM Consortium website (http://diagramconsortium.org/downloads.html)³³, summary statistics for asthma were retrieved from GWAS 392 Catalog (https://www.ebi.ac.uk/gwas/)⁶¹, and those for bipolar disorder and schizophrenia were 393 394 website44,61,62 accessed from the Psychiatric Genomics Consortium 395 (https://www.med.unc.edu/pgc/download-results/). Lastly, GWAS summary statistics for 396 Alzheimer's disease (excluding 23andme data) were downloaded from the CTG Lab website⁶³ 397 (https://ctg.cncr.nl/software/summary statistics).

398

Analyses. *Drug gene-set analysis.* Drug gene-sets were created using the gene targets and interactions retrieved from both the Clue Repurposing Hub and Drug Gene Interaction Database for every compound, resulting in 1201 drug gene sets with $n \ge 2$. Additionally, we created 3 types of drug gene-set by grouping drugs by clinical indication (n = 515), by mechanism of action

403 (n = 354), and by ATC III code (n = 164). Competitive gene-set analysis was performed separately 404 with MAGMA v1.09b for each type of drug-gene set, using the 1K Genomes European reference 405 panel^{19,64}. Competitive gene set analysis was computed while conditioning on a gene set of every 406 gene target in our data set (n = 2281) to assess whether drug gene-set associations were specific 407 to the drug-gene set or driven by common properties of drug target genes.

408

409 *Drug group associations*. Groups of drugs were examined for enrichment of genetic signal using a 410 multiple linear regression model to estimate the effect of drug group membership on MAGMA t-411 statistics. Given that the MAGMA t-statistic is a measure of the degree to which a drug gene set is 412 enriched for genetic signal for a phenotype, this allows us to test whether drugs in that drug group 413 exhibited (on average) greater enrichment than other drugs.

414 Denoting the vector of drug gene-set t-statistics as Y and encoding a binary indicator 415 variable G_i for drug group *j*, scored 1 for drugs in that drug group and 0 otherwise, we fit the 416 model $Y = \beta_0 + C\beta_c + G_i\beta_G + \varepsilon = X\beta + \varepsilon$. Here, *C* is a covariate matrix containing the drug gene-417 set size as well as the log of the drug gene-set size, and ε is the residual term with distribution 418 $\varepsilon \sim MVN(0, \sigma^2 S)$, where S is the sampling correlation matrix of the MAGMA t-statistics. Combining 419 the intercept and predictor variables in X, the model can be estimated using Generalized Least Squares, yielding the estimate $\hat{\beta} = (X^T S^{-1} X)^{-1} X^T S^{-1} Y$, with sampling covariance matrix W =420 $\hat{\sigma}^2 (X^T S^{-1} X)^{-1}$. For the residual variance we have the estimate $\hat{\sigma}^2 = \frac{\hat{\varepsilon}^T S^{-1} \hat{\varepsilon}}{N-K}$, with $\hat{\varepsilon} = Y - X\hat{\beta}$ and 421 422 with N the number of drugs and K = 4 the number of parameters in the regression equation.

423 For each drug group *j*, we test the null hypothesis $H_0: \beta_G = 0$ against the one-sided 424 alternative $H_A: \beta_G > 0$ using the test statistic $T = \frac{\hat{\beta}_G}{\sqrt{W_G}}$, where W_G is the diagonal element of *W* 425 corresponding to $\hat{\beta}_G$ and *T* has a t-distribution with N - K degrees of freedom. Correction for

426 multiple tests was done using a two-stage Bonferroni correction, correcting for the three grouping 427 methods used and then for the number of groups tested within each grouping method. This 428 resulted in a threshold of $0.05/N_g/3$ for each grouping method g with N_g the number of groups 429 for g, where $N_g = 85$ for the ATC III code drug groups, $N_g = 79$ for the mechanism of action drug 430 groups, and $N_g = 118$ for the clinical indication drug groups.

431

Manhattan Plots of Genes Targeted by Approved Drugs. The Bonferroni-significant thresholds for the 433 gene-level Manhattan plots were derived by $0.05/N_{x,y}$, where N_x is the number of genes tested in 434 MAGMA for a phenotype y. The Bonferroni-significant thresholds are as follows: $p_{hypercholeterolemia} = 0.05/17493 = 2.86E-06, p_{diabetes} = 0.05/11631 = 4.29E-06, p_{cad} =$ $0.05/18180 = 2.75E-06, p_{asthma} = 0.05/18315 = 2.73E-06, p_{schizophrenia} = 0.05/18265 =$ $2.74E-06, p_{bipolar} = 0.05/18262 = 2.74E-06, p_{parkinsons} = 0.05/18367 = 2.72E-06, p_{alzheimers} =$ 0.05/18409 = 2.72E-06.

439

440 Drug Similarity Network Graphs. Network graphs were created to investigate how the top results 441 cluster based on the similarity of their gene targets. The similarity of each pair of drugs was 442 evaluated using the Jaccard similarity coefficient, which is calculated using the formula I(A, B) = $\frac{|A \cap B|}{|A \cup B|}$ for drug gene sets A and B, where $|A \cap B|$ denotes the number of genes shared by those 443 444 gene sets and $|A \cup B|$ the number of genes that occurs in at least one of the two gene sets. Central 445 nodes for each phenotype were defined as drug-gene sets with a MAGMA gene-set analysis p-value 446 < 0.01, and all drugs with a Jaccard index >= 0.25 with a central node were included as 447 peripheral nodes. Network graphs were created in Python using the package networkx 2.6.3.

449	URLs. (CTG La	ab, <u>https://ctg.cn</u>	<u>cr.nl/software/s</u>	ummary_s	<u>tatistics</u> ; (GWAS	Atlas,
450	https://atla	s.ctglab.n	/; GWAS Catalog,	https://www.eb	i.ac.uk/gw	<u>as/;</u> Drug G	ene Inte	raction
451	Database,	<u>https:</u>	//www.dgidb.org/;	DIAGRAM	Conso	ortium, <u>l</u>	nttp://dia	agram-
452	<u>consortium.</u>	org/dowr	<u>lloads.html</u>);	Psychiatric	Gen	iomics	Conso	ortium,
453	https://www	w.med.un	c.edu/pgc/download	-results/;	Clue	Repurposi	ng	Hub,
454	https://clue	.io/repur	posing; MAGMA, http	os://ctg.cncr.nl/	software/n	nagma.		

455

456 **Code availability**

457 The software pipeline used to compute drug gene-set analysis and the drug group analyses is 458 publicly available and can be accessed here: <u>https://github.com/nybell/drugsets</u>.

459

460 Acknowledgments

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 964874. DP is supported by the Netherlands Organization for Scientific Research - Gravitation project 'BRAINSCAPES: A Roadmap from Neurogenetics to Neurobiology' (024.004.012), and DP and EU are funded by the European Research Council advanced grant 'From GWAS to Function' (ERC-2018-ADG 834057). NYB, EU, EvW, and DP have no conflicts of interest to declare. CdL was funded by F. Hoffman-La Roche AG.

468		References
469	1.	Welter, D. et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations.
470		Nucl. Acids Res. 42, D1001–D1006 (2014).
471	2.	Visscher, P. M. et al. 10 Years of GWAS Discovery: Biology, Function, and Translation.
472		The American Journal of Human Genetics 101, 5–22 (2017).
473	3.	Nelson, M. R. et al. The support of human genetic evidence for approved drug indications.
474		Nat Genet 47, 856–860 (2015).
475	4.	King, E. A., Davis, J. W. & Degner, J. F. Are drug targets with genetic support twice as
476		likely to be approved? Revised estimates of the impact of genetic support for drug
477		mechanisms on the probability of drug approval. PLoS Genet 15, e1008489 (2019).
478	5.	Ochoa, D. et al. Human genetics evidence supports two-thirds of the 2021 FDA-approved
479		drugs. Nature Reviews Drug Discovery (2022) doi:10.1038/d41573-022-00120-3.
480	6.	Wang, K. et al. Diverse Genome-wide Association Studies Associate the IL12/IL23 Pathway
481		with Crohn Disease. The American Journal of Human Genetics 84, 399–405 (2009).
482	7.	Moschen, A. R., Tilg, H. & Raine, T. IL-12, IL-23 and IL-17 in IBD: immunobiology and
483		therapeutic targeting. Nat Rev Gastroenterol Hepatol 16, 185–196 (2019).
484	8.	Dickson, M. & Gagnon, J. P. Key factors in the rising cost of new drug discovery and
485		development. Nat Rev Drug Discov 3, 417–429 (2004).
486	9.	DiMasi, J. A., Grabowski, H. G. & Hansen, R. W. Innovation in the pharmaceutical industry:
487		New estimates of R&D costs. Journal of Health Economics 47, 20–33 (2016).
488	10.	Scannell, J. W., Blanckley, A., Boldon, H. & Warrington, B. Diagnosing the decline in
489		pharmaceutical R&D efficiency. Nat Rev Drug Discov 11, 191–200 (2012).
490	11.	Hyman, S. E. Psychiatric Drug Development: Diagnosing a Crisis. 11 (2013).

- 491 12. Lau, A. & So, H.-C. Turning genome-wide association study findings into opportunities for
- drug repositioning. *Computational and Structural Biotechnology Journal* 18, 1639–1650
 (2020).
- 494 13. Liu, J. Z. *et al.* Association analyses identify 38 susceptibility loci for inflammatory bowel
- disease and highlight shared genetic risk across populations. *Nat Genet* **47**, 979–986 (2015).
- 496 14. Schmidt, A. F. et al. Genetic drug target validation using Mendelian randomisation. Nat
- 497 *Commun* **11**, 3255 (2020).
- 498 15. Reay, W. R. & Cairns, M. J. Advancing the use of genome-wide association studies for drug
 499 repurposing. *Nat Rev Genet* (2021) doi:10.1038/s41576-021-00387-z.
- 500 16. So, H.-C. *et al.* Analysis of genome-wide association data highlights candidates for drug
 501 repositioning in psychiatry. *Nat Neurosci* 20, 1342–1349 (2017).
- 502 17. Gaspar, H. A. & Breen, G. Drug enrichment and discovery from schizophrenia genome-wide
- association results: an analysis and visualisation approach. *Sci Rep* 7, 12460 (2017).
- 504 18. de Jong, S., Vidler, L. R., Mokrab, Y., Collier, D. A. & Breen, G. Gene-set analysis based on
- 505 the pharmacological profiles of drugs to identify repurposing opportunities in schizophrenia.
- 506 *J Psychopharmacol* **30**, 826–830 (2016).
- 507 19. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized Gene-Set
 508 Analysis of GWAS Data. *PLoS Comput Biol* 11, e1004219 (2015).
- 20. de Leeuw, C. A., Neale, B. M., Heskes, T. & Posthuma, D. The statistical properties of geneset analysis. *Nat Rev Genet* 17, 353–364 (2016).
- 511 21. Gaspar, H. A., Hübel, C. & Breen, G. Drug Targetor: a web interface to investigate the
- 512 human druggome for over 500 phenotypes. *Bioinformatics* **35**, 2515–2517 (2019).

- 513 22. Corsello, S. M. et al. The Drug Repurposing Hub: a next-generation drug library and
- 514 information resource. *Nat Med* **23**, 405–408 (2017).
- 515 23. Freshour, S. L. et al. Integration of the Drug–Gene Interaction Database (DGIdb 4.0) with
- 516 open crowdsource efforts. *Nucleic Acids Research* **49**, D1144–D1151 (2021).
- 517 24. Plosker, G. L. & Figgitt, D. P. Repaglinide: A Pharmacoeconomic Review of its Use in Type
- 518 2 Diabetes Mellitus. *PharmacoEconomics* **22**, 389–411 (2004).
- 519 25. Phillippe, H. M. & Wargo, K. A. Mitiglinide for type 2 diabetes treatment. *Expert Opinion*520 *on Pharmacotherapy* 14, 2133–2144 (2013).
- 521 26. Dahlén, A. D. et al. Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New
- 522 Drugs in Clinical Trials and Global Sales. *Front. Pharmacol.* **12**, 807548 (2022).
- 523 27. Maron, D. J., Fazio, S. & Linton, M. F. Current Perspectives on Statins. *Circulation* 101,
 524 207–213 (2000).
- 525 28. Alonso, R., Cuevas, A. & Mata, P. Lomitapide: a review of its clinical use, efficacy, and
 526 tolerability. *Core Evid* 14, 19–30 (2019).
- 527 29. Keating, G. M. & Croom, K. F. Fenofibrate: A Review of its Use in Primary Dyslipidaemia,
- 528 the Metabolic Syndrome and Type 2 Diabetes Mellitus. *Drugs* 67, 121–153 (2007).
- 30. Libby, P. & Theroux, P. Pathophysiology of Coronary Artery Disease. *Circulation* 111,
 3481–3488 (2005).
- 531 31. Ahmed, S. *et al.* Use of Gabapentin in the Treatment of Substance Use and Psychiatric
- 532 Disorders: A Systematic Review. *Frontiers in Psychiatry* **10**, (2019).
- 533 32. Clark, S. D., Van Snellenberg, J. X., Lawson, J. M. & Abi-Dargham, A. Opioid antagonists
- are associated with a reduction in the symptoms of schizophrenia: a meta-analysis of
- 535 controlled trials. *Neuropsychopharmacol.* **45**, 1860–1869 (2020).

536	33. Mahajan, A. et al. Multi-ancestry genetic study of type 2 diabetes highlights the power of

- 537 diverse populations for discovery and translation. *Nat Genet* **54**, 560–572 (2022).
- 538 34. Mahajan, A. et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-
- density imputation and islet-specific epigenome maps. *Nat Genet* **50**, 1505–1513 (2018).
- 540 35. Banno, A., Reddy, A. T., Lakshmi, S. P. & Reddy, R. C. PPARs: Key Regulators of Airway
- 541 Inflammation and Potential Therapeutic Targets in Asthma. *Nucl Receptor Res* 5, 101306
- 542 (2018).
- 543 36. Berger, W. E., Schenkel, E. J., Mansfield, L. E., & Desloratadine Study Group. Safety and
- 544 efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal
- 545 congestion. Ann Allergy Asthma Immunol **89**, 485–491 (2002).
- 546 37. Stefanowicz, D. *et al.* Epigenetic modifying enzyme expression in asthmatic airway
 547 epithelial cells and fibroblasts. *BMC Pulm Med* 17, 24 (2017).
- 548 38. Whelan, R., St Clair, D., Mustard, C. J., Hallford, P. & Wei, J. Study of Novel
- 549 Autoantibodies in Schizophrenia. *Schizophrenia Bulletin* **44**, 1341–1349 (2018).
- 550 39. Ripke, S. et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature
- **55**1 **511**, 421–427 (2014).
- 40. Ma, L., Shcherbina, A. & Chetty, S. Variations and expression features of CYP2D6
- 553 contribute to schizophrenia risk. *Mol Psychiatry* **26**, 2605–2615 (2021).
- 41. Claeysen, S., Bockaert, J. & Giannoni, P. Serotonin: A New Hope in Alzheimer's Disease? *ACS Chem. Neurosci.* 6, 940–943 (2015).
- 42. Jaccard, P. The Distribution of the Flora in the Alpine Zone.1. *New Phytologist* 11, 37–50
 (1912).

- 43. Hasan, A. et al. Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling
- 559 pathway for the treatment of schizophrenia: Study design and methodology of a multicenter
- 560 randomized, placebo-controlled trial. *Contemp Clin Trials Commun* **17**, 100537 (2020).
- 561 44. Mullins, N. et al. Genome-wide association study of more than 40,000 bipolar disorder cases
- 562 provides new insights into the underlying biology. *Nat Genet* **53**, 817–829 (2021).
- 563 45. Agrawal, R. The first approved agent in the Glitazar's Class: Saroglitazar. *Curr Drug*
- 564 *Targets* **15**, 151–155 (2014).
- 565 46. Aravind Sosale, S., Saboo, B. & Sosale, B. Saroglitazar for the treatment of
- 566 hypertriglyceridemia in patients with type 2 diabetes: current evidence. *DMSO* 189 (2015)
- 567 doi:10.2147/DMSO.S49592.
- 47. Rizek, P., Kumar, N. & Jog, M. S. An update on the diagnosis and treatment of Parkinson
 disease. *CMAJ* 188, 1157–1165 (2016).
- 570 48. Cummings, J. New approaches to symptomatic treatments for Alzheimer's disease.
- 571 *Molecular Neurodegeneration* **16**, 2 (2021).
- 572 49. Stępnicki, P., Kondej, M. & Kaczor, A. A. Current Concepts and Treatments of
- 573 Schizophrenia. *Molecules* **23**, 2087 (2018).
- 574 50. McIntyre, R. S. *et al.* Bipolar disorders. *The Lancet* **396**, 1841–1856 (2020).
- 575 51. Harrison, P. J., Tunbridge, E. M., Dolphin, A. C. & Hall, J. Voltage-gated calcium channel
- 576 blockers for psychiatric disorders: genomic reappraisal. *Br J Psychiatry* **216**, 250–253
- 577 (2020).
- 578 52. Hayes, J. F. et al. Association of Hydroxylmethyl Glutaryl Coenzyme A Reductase
- 579 Inhibitors, L-Type Calcium Channel Antagonists, and Biguanides With Rates of Psychiatric

- Hospitalization and Self-Harm in Individuals With Serious Mental Illness. *JAMA Psychiatry* **76**, 382 (2019).
- 582 53. Van Dyke, P. & Thomas, K. L. Concomitant calcium channel blocker and antipsychotic
- 583 therapy in patients with schizophrenia: Efficacy analysis of the CATIE-Sz phase 1 data. Ann
- 584 *Clin Psychiatry* **30**, 6–16 (2018).
- 585 54. Lintunen, J., Lähteenvuo, M., Tiihonen, J., Tanskanen, A. & Taipale, H. Adenosine
- 586 modulators and calcium channel blockers as add-on treatment for schizophrenia. *npj*
- 587 *Schizophr* **7**, 1–7 (2021).
- 588 55. Wishart, D. S. *et al.* DrugBank 5.0: a major update to the DrugBank database for 2018.
- 589 *Nucleic Acids Research* **46**, D1074–D1082 (2018).
- 56. Lawlor, D. A., Tilling, K. & Davey Smith, G. Triangulation in aetiological epidemiology. *International Journal of Epidemiology* 45, 1866–1886 (2016).
- 592 57. Werme, J., Sluis, S. van der, Posthuma, D. & Leeuw, C. A. de. LAVA: An integrated
- *framework for local genetic correlation analysis.* 2020.12.31.424652
- 594 https://www.biorxiv.org/content/10.1101/2020.12.31.424652v2 (2021)
- 595 doi:10.1101/2020.12.31.424652.
- 58. Willer, C. J. *et al.* Discovery and refinement of loci associated with lipid levels. *Nat Genet*45, 1274–1283 (2013).
- 598 59. Nalls, M. A. et al. Identification of novel risk loci, causal insights, and heritable risk for
- 599 Parkinson's disease: a meta-analysis of genome-wide association studies. *The Lancet*
- 600 *Neurology* **18**, 1091–1102 (2019).
- 601 60. Watanabe, K. et al. A global overview of pleiotropy and genetic architecture in complex
- 602 traits. Nat Genet **51**, 1339–1348 (2019).

- 603 61. Han, Y. *et al.* Genome-wide analysis highlights contribution of immune system pathways to
 604 the genetic architecture of asthma. *Nat Commun* 11, 1776 (2020).
- 605 62. Consortium, T. S. W. G. of the P. G., Ripke, S., Walters, J. T. & O'Donovan, M. C. Mapping
- 606 genomic loci prioritises genes and implicates synaptic biology in schizophrenia.
- 607 2020.09.12.20192922 https://www.medrxiv.org/content/10.1101/2020.09.12.20192922v1
- 608 (2020) doi:10.1101/2020.09.12.20192922.
- 609 63. Wightman, D. P. et al. A genome-wide association study with 1,126,563 individuals
- 610 identifies new risk loci for Alzheimer's disease. *Nat Genet* **53**, 1276–1282 (2021).
- 611 64. Auton, A. *et al.* A global reference for human genetic variation. *Nature* **526**, 68–74 (2015).